Update in tuberculosis and nontuberculous mycobacterial disease 2012

American Journal of Respiratory and Critical Care Medicine

Volumn 188, Issue 8, 2013, Pages 923-927

  Menzies, Dick ^a   Nahid, Payam ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZITHROMYCIN; BCG VACCINE; BEDAQUILINE; CLARITHROMYCIN; CULTURE FILTRATE PROTEIN 10; DELAMANID; DOXYCYCLINE; EARLY SECRETORY ANTIGENIC TARGET 6; ETHAMBUTOL; ISONIAZID; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PREDNISONE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE;

AREA UNDER THE CURVE; ARTICLE; ATYPICAL MYCOBACTERIUM; BCG VACCINATION; BODY MASS; CD8+ T LYMPHOCYTE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOGENICITY; INFECTION RATE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; RISK FACTOR; SURGICAL MASK; TREATMENT DURATION; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; HUMANS; LATENT TUBERCULOSIS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; TUBERCULOSIS, PULMONARY;

EID: 84886393334     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201304-0687UP     Document Type: Article

References (34)

1. Ye ZJ, Zhou Q, Yuan ML, Du RH, Yang WB, Xiong XZ, Huang B, Shi HZ. Differentiation and recruitment of IL-22-producing helper T cells stimulated by pleural mesothelial cells in tuberculous pleurisy. Am J Respir Crit Care Med 2012;185:660-669.
2. Walker NF, Clark SO, Oni T, Andreu N, Tezera L, Singh S, Saraiva L, Pedersen B, Kelly DL, Tree JA, et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am J Respir Crit Care Med 2012;185:989-997.
3. Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, Tadokera R, Conesa-Botella A, Seldon R, Rangaka MX, Rebe K, Pepper DJ, et al. Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2012;186:369-377.
4. Fennelly KP, Jones-López EC, Ayakaka I, Kim S, Menyha H, Kirenga B, Muchwa C, Joloba M, Dryden-Peterson S, Reilly N, et al. Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2012;186:450-457.
5. Dharmadhikari AS, Mphahlele M, Stoltz A, Venter K, Mathebula R, Masotla T, Lubbe W, Pagano M, First M, Jensen PA, et al. Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward. Am J Respir Crit Care Med 2012;185:1104-1109.
6. Machingaidze S, Verver S, Mulenga H, Abrahams DA, Hartherill M, Hanekom W, Hussey GD, Mahomed H. Predictive value of recent QuantiFERON conversation for tuberculosis disease in adolescents. Am J Respir Crit Care Med 2012;186:1051-1056.
7. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med 2012;185:779-784.
8. Basu Roy R, Sotgiu G, Altet-Gómez N, Tsolia M, Ruga E, Velizarova S, Kampmann B. Identifying predictors of interferon-g release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study. Am J Respir Crit Care Med 2012;186:378-384.
9. Mancuso JD, Mazurek GH, Tribble D, Olsen C, Aronson NE, Geiter L, Goodwin D, Keep LW. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med 2012;185:427-434.
10. Lancioni C, Nyendak M, Kiguli S, Zalwango S, Mori T, Mayanja-Kizza H, Balyejusa S, NullM, Baseke J,Mulindwa D, et al.; Tuberculosis Research Unit. CD81 T cells provide an immunologic signature of tuberculosis in young children. Am J Respir Crit Care Med 2012;185:206-212.
11. Barnard M, Warren R, Van Pittius NG, van Helden P, Bosman M, Streicher E, Coetzee G, O'Brien R. Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med 2012;186:1298-1305.
12. Cohen J. Infectious disease: approval of novel TB drug celebrated-with restraint. Science 2013;339:130.
13. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56:3271-3276.
14. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-2405.
15. Janssen briefing document. TMC207 (bedaquiline): treatment of patients with MDR-TB: NDA 204-384. 2012 [accessed 2013 May 1]. U.S. Food and Drug Administration. Available from: http://www.fda.gov/ downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Anti- InfectiveDrugsAdvisoryCommittee/UCM329260.pdf
16. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-2160.
17. Cain KP, Garman KN, Laserson KF, Ferrousier-Davis OP, Miranda AG, Wells CD, Haley CA. Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee. Am J Respir Crit Care Med 2012;186:273-279.
18. Bhargava A, Pai M, Bhargava M, Marais BJ, Menzies D. Can social interventions prevent tuberculosis? The Papworth experiment (1918-1943) revisited. Am J Respir Crit Care Med 2012;186:442-449.
19. Shapiro AE, Variava E, Rakgokong MH, Moodley N, Luke B, Salimi S, Chaisson RE, Golub JE, Martinson NA. Community-based targeted case finding for tuberculosis and HIV in household contacts of patients with tuberculosis in South Africa. Am J Respir Crit Care Med 2012;185: 1110-1116.
20. Ritz N, Dutta B, Donath S, Casalaz D, Connell TG, Tebruegge M, Robins-Browne R, Hanekom WA, Britton WJ, Curtis N. The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial. Am J Respir Crit Care Med 2012;185:213-222.
21. Scriba TJ, Tameris T, Smit E, van der Merve L, Hughes EJ, Kadira B, et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV-and/ormycobacterium. Am J Respir Crit Care Med 2012;185: 769-778.
22. Tamerais MD, Hatheril M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet (In press)
23. Dirac MA, Horan KL, Doody DR, Meschke JS, Park DR, Jackson LA, Weiss NS, Winthrop KL, Cangelosi GA. Environment or host? A case-control study of risk factors for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;186:684-691.
24. Adjemian J, Olivier KN, Seitz AE, Falkinham JO III, Holland SM, Prevots DR. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 2012;186: 553-558.
25. Palmer CE, Edwards LB. Sensitivity to mycobacterial PPD antigens with some laboratory evidence of its significance. Tuberkuloza 1966;18: 193-200.
26. McCarthy KD, Cain KP, Winthrop KL, Udomsantisuk N, Lan NTN, Sar B, Kimerling ME, Kanara N, Lynen L, Monkongdee P, et al. Nontuberculous mycobacterial disease in patients with HIV in Southeast Asia. Am J Respir Crit Care Med 2012;185:981-988.
27. Adjemian J, Olivier KN, Seitz AE, Hollard SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012;185:881-886.
28. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;185:575-583.
29. van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012;186: 559-565.
30. Koh WJ, Jeong BH, Jeon K, Lee SY, Shin SJ. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;186:797-802.
31. Choi GE, Shin SJ, Won CJ, Min KN, Oh T, Hahn MY, Lee K, Lee SH, Daley CL, Kim S, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012;186:917-925.
32. Schluger NW. Treatment of pulmonary Mycobacterium avium complex infections: do drug levels matter? Am J Respir Crit Care Med 2012; 186:710-711.
33. Stout JE, Floto RA. Treatment of Mycobacterium abscessus: all macrolides are equal, but perhaps some are more equal than others. Am J Respir Crit Care Med 2012;186:822-823.
34. Griffith DE, Winthrop KL. Mycobacterium avium complex lung disease therapy. Am J Respir Crit Care Med 2012;186:477-479.